Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025
Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's website at ir.venusconcept.com.
For those unable to participate, a replay of the call will be available for two weeks at: 877-660-6853 (201-612-7415 for international callers); access code 13753054. The webcast will be archived at ir.venusconcept.com.
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 12 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa PRO, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.
CONTACT: Investor Relations Contact: ICR Healthcare on behalf of Venus Concept Mike Piccinino, CFA VenusConceptIR@ICRHealthcare.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
an hour ago
- Boston Globe
Doug Flutie joins Eastern Bank's push to revive the Brockton Rox, as a pitcher
It all started with New York Boulders owner Bill Janetschek's decision to buy both the Rox name, which had been used by a college team, and the New England Knockouts team, which was playing in Campanelli as part of the Frontier League. The Janetschek-led ownership group acquired the Knockouts and renamed the team the Rox, a callback to the pro team that previously drew crowds to the 4,750-seat stadium. Advertisement Mayor Bob Sullivan approached Eastern Bank executive chair Bob Rivers about helping the ownership team (which includes Red Sox legend Jim Rice, and Rox team president Shawn Reilly) revive the Rox. Rivers had heard this story before, with different owners. But he realized Janetschek, the retired chief financial officer of private equity giant KKR, might have the wherewithal to pull it off. So Rivers and his staff held weekly calls with the new Rox ownership to brainstorm ways to drive traffic to the Rox games, and in turn help bring more people into Brockton to support local businesses. Advertisement Janetschek said there has been a significant uptick in attendance this summer after a choppy spring, in large part due to Rivers's help. Janetschek has started talking with Sullivan about a longer lease to use the city-owned stadium. 'If Bob Rivers wasn't here, I don't know if we would have made it through the season,' Janetschek said. 'It's ... helping build his brand for Eastern as well as introducing and building the brand for the Rox.' At one point during these weekly calls, the idea of recruiting Flutie, who was already working with Eastern, came up. The former New England Patriot had galvanized the crowd at a Savannah Bananas game in June, by making the first pitch and then not leaving the mound until the game was over. This time, though, he'll be playing in an actual competition. Janetschek needed to get clearance from Frontier League commissioner Steve Tahsler for Flutie to join the Rox pitching roster, even for one inning. 'He's not just showing up and signing autographs,' Rivers said. This will also be the first time that Rivers is testing the football skills of his longtime lieutenant, with a charity football toss in front of the crowd. 'It's not going to be embarrassing at all,' Rivers said. 'Doug knows how to throw a football for sure. And Quincy knows how to catch it.' Advertisement This is an installment of our weekly Bold Types column about the movers and shakers on Boston's business scene. Jon Chesto can be reached at
Yahoo
2 hours ago
- Yahoo
UK's South Eastern Railway implements IsoMat tech to mitigate heat issues
The South Eastern Railway has collaborated with Flint Engineering, a UK-based green technology start-up, to address the issue of excessive heat in railway signalling cabinets on the Tonbridge to Hastings line. The new IsoMat system, which is patented and does not require any power, maintenance, or modifications to the internal cabinet, can be installed in under an hour and is designed to manage internal temperatures that can exceed 70°C. The deployment will focus on ten of the Kent Route's most vulnerable cabinet locations this summer. Flint Engineering's IsoMat technology has demonstrated the ability to reduce peak temperatures by more than 21% on the hottest days, utilising a passive heat exchanger installed on the cabinet roofs. The system employs a flat aluminium sheet design with an internal network of sealed channels, allowing for efficient thermal energy transfer. This approach is said to significantly outperform traditional materials such as copper and aluminium in heat dissipation. Following a successful pilot trial, Flint Engineering is preparing to increase the number of IsoMat units for broader deployment across additional high-risk cabinet locations by summer 2026. South Eastern Railway chief operating officer David Davidson said: 'Flint's IsoMat technology provides a simple, effective solution to a complex problem, helping us maintain service reliability even during heatwaves without requiring power, maintenance or complicated installation procedures.' This initiative is part of an effort to explore sustainable solutions to climate change impacts, including passive cooling technologies, in collaboration with Network Rail's Technical Authority and Contracts & Procurement department. Network Rail, which oversees a vast network of rail infrastructure, has faced challenges related to high internal temperatures in signalling cabinets, which can lead to operational disruptions and increased maintenance costs. The introduction of the IsoMat system is expected to alleviate these issues, thereby improving overall rail reliability. Flint Engineering is also commencing commercial production of the IsoMat technology this year, with interest from markets in the UK, North America, and the Middle East. The technology has potential applications beyond railways, including sectors such as construction and commercial refrigeration, where effective temperature management is essential. Flint Engineering CEO Mark Robinson said: 'Our partnership with Network Rail represents a perfect application of our technology where it can make a real difference to critical infrastructure. 'The IsoMat demonstrates how innovative engineering can address climate resilience challenges while delivering significant operational benefits.' In June this year, Network Rail, Neos Networks, and Freshwave launched Project Reach, a partnership focused on eradicating mobile signal blackspots along Britain's major rail routes. "UK's South Eastern Railway implements IsoMat tech to mitigate heat issues " was originally created and published by Railway Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
3 hours ago
- Yahoo
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI). Managing blood pressure instability is a major unmet need after SCI, with a significant impact on cardiovascular health and quality of life. Approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe are expected to participate. EINDHOVEN, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption for the ARC-IM System. With this approval, the Company can initiate the Empower BP pivotal study to assess the safety and efficacy of its implantable spinal stimulation system to address blood pressure instability after SCI. Empower BP is the Company's second global pivotal study, and the first to evaluate the implantable ARC-IM System. The randomized, double-blinded, sham-controlled study is expected to involve approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe, with first patient enrollment anticipated before the end of the year. The study will target participants with injuries at spinal cord levels C2-T6, injury severities of AIS A-D, and blood pressure instability characterized by chronic orthostatic hypotension (OH) and episodes of autonomic dysreflexia (AD). 'This is an important milestone for ONWARD and the SCI community,' said Dave Marver, CEO of ONWARD. 'Our ARC-IM System is designed to address several unmet needs, including blood pressure instability which is a major recovery target after spinal cord injury. With this IDE approval, we continue to advance our innovation pipeline and inspire realistic hope in restoring autonomic functions and independence after SCI and other movement disabilities.' Over 50% of people with SCI experience blood pressure instability, affecting nearly 350,000 people in the US and Europe.1 Blood pressure instability and persistent low blood pressure can threaten neurological recovery and negatively impact cardiovascular health and quality of life. The most frequent symptoms include dizziness, lightheadedness, blurred vision and fatigue.2 'Blood pressure instability, especially chronic low blood pressure, is one of the most hidden and unrecognized functional complications of spinal cord injury,' explains Dr. James Guest, neurosurgeon and Professor of Neurological Surgery at the University of Miami. 'It leaves people feeling unwell and can significantly impact their overall quality of life. Blood pressure instability also increases the risk of cardiovascular disease, making addressing this unmet need critical for improving the long-term outcomes of SCI.' The ONWARD ARC-IM System is an implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation. It is the first neuroprosthetic system designed to manage blood pressure instability in people with SCI. It comprises the implanted ONWARD Neurostimulator (IPG) and the ARC-IM Thoracic Lead. The ARC-IM Thoracic Lead is optimized for surgical placement in a specific region of the thoracic spinal cord, called the 'Hemodynamic Hotspot'. The location was first discovered by the Company's research partners at the Swiss Federal Institute of Technology Lausanne (EPFL), Centre Hospitalier Universitaire Vaudois (CHUV), and the University of Calgary in a study published in Nature in January 2021.3 In December 2022, the Company announced positive top-line interim clinical results from its feasibility studies showing improved blood pressure regulation and improved hemodynamic stability after SCI. In addition to immediate and sustained improved blood pressure levels, participants taking anti-hypotension drugs prior to the study significantly reduced or discontinued their medication. Participants also reported improved general well-being and a reduction in orthostatic hypotension, including reduced dizziness and increased energy. Detailed interim results from these studies are expected to be published later this year. Managing blood pressure instability is among the major unmet needs for which the FDA has awarded the Company one of its 10 Breakthrough Device Designations. This award is reserved for novel, cutting-edge therapies addressing unmet needs and provides potential regulatory and reimbursement benefits. To stay informed about ONWARD's research studies, technologies, and the availability of therapies in your area, please complete this webform. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries, and other movement disabilities. Building on over a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed ARC Therapy. It has subsequently been awarded 10 Breakthrough Device designations from the FDA. The Company's ARC-EX® System is cleared for commercial sale in the US. The Company is also developing an investigational implantable system called ARC-IM, which can be paired with a brain-computer interface (BCI) to restore thought-driven movement. Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, please visit For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Notes and references: 1. Katzelnick CG et al. Blood Pressure Instability in Persons With SCI: Evidence From a 30-Day Home Monitoring Observation. Am J Hypertens. 2019 Sep 24;32(10):938-944 2. Carlozzi, N. E. et al. Impact of blood pressure dysregulation on health-related quality of life in persons with spinal cord injury: development of a conceptual model. Arch. Phys. Med. Rehabil. 94, 1721–1730 (2013) 3. Squair, J.W. et al. Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury. Nature 590, 308–314 (2021) Forward-Looking Statements Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
